Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial

Although classic Hodgkin lymphoma (cHL) is highly curable with current treatment paradigms, therapy fails in 10-25% of patients. This prospective multicenter phase II study attempted to investigate the efficacy and safety of the combination of tislelizumab with gemcitabine and oxaliplatin (T-GemOx)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Kaiyang, Liu, Hailing, Ma, Jie, Yang, Haiyan, Cao, Lei, Wang, Huihan, Peng, Hongling, Shi, Wei, Zhao, Xiaoli, Wu, Wei, Zhu, Huayuan, Li, Jianyong, Fan, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Hodgkin Lymphoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388287/
https://www.ncbi.nlm.nih.gov/pubmed/36700408
http://dx.doi.org/10.3324/haematol.2022.282266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388287/
https://www.ncbi.nlm.nih.gov/pubmed/36700408
http://dx.doi.org/10.3324/haematol.2022.282266

Ejemplares similares